Methods and compositions using
Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
1. A method for enhancing an immune response in a mammal to a cancerous cell present within the mammal, comprising:
administering to the mammal an effective amount of a boost dose of a vaccine comprising an attenuated Listeria that encodes an expressible, immunologically active portion of a target antigen expressed by the cancerous cell that is heterologous to the attenuated Listeria , wherein the mammal previously had been administered an effective amount of a prime dose of an inactivated tumor cell vaccine expressing a nucleic acid that encodes granulocyte macrophage-colony stimulation factor (GM-CSF).
2. The method of claim 1 , wherein the inactivated tumor cell vaccine comprises inactivated autologous tumor cells.
3. The method of claim 1 , wherein the inactivated tumor cell vaccine comprises inactivated allogeneic tumor cells.
4. The method of claim 1 , wherein the cancerous cell is an adenocarcinoma cell.
5. The method of claim 2 , wherein the cancerous cell is an adenocarcinoma cell.
6. The method of claim 3 , wherein the cancerous cell is an adenocarcinoma cell.
7. The method of claim 1 , wherein the attenuated Listeria comprises a mutation that inactivates ActA, InlB, or both ActA and InlB.
8. The method of claim 2 , wherein the attenuated Listeria is ΔactAΔinlB.
9. The method of claim 1 , wherein the attenuated Listeria is killed but metabolically active (“KBMA”).
10. The method of claim 1 , wherein the target antigen is Annexin II.